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A bdominal pain is reported by a third of school-aged chil-dren1 and accounts for several visits daily in most emer-gency departments.2–5 Although the use of analgesia to 
treat acute abdominal pain is well-supported,6,7 there is little evi-
dence to guide the management of nonspecific abdominal pain in 
the emergency department,8 which accounts for two-thirds of cases 
of abdominal pain presenting to the emergency department.8,9 
Acetaminophen is the most commonly used World Health Organ-
ization Step 1 analgesic.10 In children, it is effective for many painful 
conditions,11,12 but data supporting its use for abdominal pain are 
lacking.13,14 Despite strong advocacy by the American Academy of 
Pediatrics15 for adequate pain management, less than two-thirds of 
children with abdominal pain in the emergency department receive 
analgesia,16,17 and roughly half experience ongoing pain after dis-
charge.18 Children with nonspecific abdominal pain are less likely 
than those with a specific cause to receive analgesia.5 Available 
analgesic options for children with nonspecific abdominal pain in 
the emergency department may result in greater adherence to the 
American Academy of Pediatrics recommendations.
Hyoscine butylbromide is orally administered and available in 
most Canadian emergency departments. We surmised that it may 
be effective for colicky abdominal pain owing to its antispasmodic 
properties.19 Ten placebo-controlled studies involving 3699 adults 
with functional abdominal pain showed hyoscine butylbromide to 
be beneficial, without serious adverse effects.20–29 In the only pedi-
atric study, hyoscine butylbromide, 10 mg given orally, was found 
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ABSTRACT
BACKGROUND: Less than two-thirds of 
children with abdominal pain in the 
emergency department receive analge-
sia. We sought to determine whether 
hyoscine butylbromide was superior to 
acetaminophen for children with non-
specific colicky abdominal pain.
METHODS: We randomly allocated chil-
dren aged 8–17  years with nonspecific 
colicky abdominal pain who presented to 
the pediatric emergency department of 
London Health Sciences Centre, London, 
Ontario to receive hyoscine butylbro-
mide, 10 mg given orally, or acetamino-
phen, 15 mg/kg given orally (maximum 
975 mg). We considered the minimal clin-
ically important difference for the pri-
mary outcome (self-reported pain at 
80 min) to be 13 mm on a 100 mm visual 
analogue scale. Secondary outcomes 
included administration of rescue anal-
gesia, adverse effects and pain score less 
than 30 mm at 80 minutes.
RESULTS: A total of 236  participants 
(120 in the hyoscine butylbromide 
group and 116 in the acetaminophen 
group) were included in the trial. The 
mean visual analogue scale scores 
at  80  minutes were 29  mm (standard 
deviation [SD] 26  mm) and 30  mm 
(SD 29  mm) with hyoscine butylbro-
mide and acetaminophen, respectively 
(adjusted difference 1, 95% confidence 
interval –7 to 7). Rescue analgesia was 
administered to 4  participants (3.3%) 
in the hyoscine butylbromide group 
and 1 participant (0.9%) in the aceta-
minophen groups (p  = 0.2). We found 
no significant differences in rates of 
adverse effects between hyoscine 
butylbromide (32/116 [27.6%]) and 
acetaminophen (28/115 [24.3]) (p  = 
0.5); no serious adverse effects were 
observed. The proportion with a pain 
score less than 30  mm at 80 minutes 
was 66 (55.0%) with hyoscine butylbro-
mide and 63 (54.3%) with acetamino-
phen (p = 0.9).
INTERPRETATION: Hyoscine butylbro-
mide was not superior to acetamino-
phen in this setting. Both agents were 
associated with clinically important pain 
reduction, and either can be considered 
for children presenting to the emer-
gency department with nonspecific col-
icky abdominal pain. Trial registration: 
Clinicaltrials.gov, no. NCT02582307
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to be beneficial compared to a homeopathic preparation in 
204 children, with no serious adverse effects.30 We sought to deter-
mine whether hyoscine butylbromide was superior to acetamino-
phen in relieving pain among children presenting to the emer-
gency department with nonspecific colicky abdominal pain.
Methods
Study design and setting
We conducted a double-blind randomized trial to test the hypothesis 
that hyoscine butylbromide is superior to acetaminophen for chil-
dren with nonspecific colicky abdominal pain. Research assistants 
(K.K., S.B., S.E., E.D.) screened consecutive potentially eligible partici-
pants in the pediatric emergency department of London Health Sci-
ences Centre, London, Ontario, daily between the hours of 1700 and 
2400 from Mar. 20, 2017, to Dec. 3, 2018. The emergency department 
has an annual census of 38 000 visits and is the only pediatric surgical 
referral centre in southwestern Ontario. 
Participant selection
We included children aged 8–17 years with abdominal pain self-
reported as “crampy,” “coming in waves” or “squeezing,” and 
rated as 40 mm on a 100 mm visual analogue scale31 at its least 
intense. Pain was assessed immediately before enrolment. Chil-
dren were excluded if they were unable to swallow pills or com-
municate verbally, currently used an anticholinergic, had hyper-
sensitivity to acetaminophen, hyoscine butylbromide or 
applesauce vehicle, had received acetaminophen or hyoscine 
butylbromide within 6 hours of enrolment, had incurred abdom-
inal trauma within 48 hours of enrolment or had medical record 
evidence of abdominal or genitourinary disease; those in whom a 
surgical or medical cause for the pain (e.g., appendicitis, renal 
colic, bowel obstruction) was suspected clinically or radiographic-
ally were also excluded. The full study protocol is provided in 
Appendix 1 (available at www.cmaj.ca/lookup/doi/10.1503/
cmaj.201055/tab -related-content).We used a 5-member focus 
group of caregivers of children with abdominal pain to inform the 
terminology for describing colicky abdominal pain, lower age limit 
for swallowing pills, and consent and assent forms.
Participants were randomly allocated in a 1:1 allocation ratio with 
permuted block sizes to either single-dose hyoscine butylbromide in 
tablet form, 10 mg given orally (Boehringer Ingelheim),30 plus placebo 
acetaminophen liquid (Perrigo); or acetaminophen liquid, 15 mg/kg 
given orally to a maximum of 975 mg (McNeil Consumer Healthcare) 
plus placebo hyoscine butylbromide tablet (Perrigo). Preparation of 
medications, allocation concealment and implementation of ran-
domization were pharmacy controlled. The randomization list was 
generated with a computer-based random-number generator  (www.
randomization.com). Allocation concealment was performed by 
means of sequentially numbered, opaque, sealed envelopes.
Medications were administered by the bedside nurse. If the 
patient vomited within 30  minutes of receiving the medication, 
another dose was given. Rescue analgesia was permitted at any 
time. Blinded parties included the participant, caregiver, emer-
gency department personnel and all members of the study team 
apart from the pharmacist.
Outcomes
Outcome data were collected by research assistants (K.K., S.B., S.E., 
E.D.) using an iPad hosting the Research Electronic Data Capture 
(REDCap) platform.32 The primary outcome was self-reported pain 
80 minutes after the intervention, assessed with a 100 mm visual ana-
logue scale.33 Eighty minutes reflects the time to peak analgesic action 
of hyoscine butylbromide19 and acetaminophen (60–90 min).34,35 The 
visual analogue scale has been used in trials of analgesics in children 
older than 6 years of age36,37 and there are abundant data establishing 
its reliability.38–43 Secondary outcomes included rescue analgesia, 
adverse effects and a visual analogue scale pain score less than 
30 mm after the intervention, the World Health Organization target for 
effective analgesia.44 The following adverse effects were considered 
serious: hospital admission due to a drug-related event, prolongation 
of existing hospital stay, persistent or major disability or incapacity, a 
life-threatening outcome and death. Other secondary outcomes 
included caregiver satisfaction with pain management, assessed with 
a Likert scale ranging from 1 (very unsatisfied) to 5 (very satisfied), self-
reported pain scores 15, 30, 45 and 60 minutes after the intervention, 
return visits to a health care provider, missed surgical diagnoses 
within 72 hours of emergency department discharge, emergency 
department length of stay, discharge diagnosis, disposition and time 
to a 20% reduction in preintervention pain (Appendix 2, available at 
www.cmaj.ca/lookup/doi/10.1503/cmaj.201055/tab-related-content). 
All outcomes were prespecified except pain after discharge, length of 
emergency department stay and missed surgical diagnoses (data col-
lected by means of a telephone survey with caregivers at 72 h, as 
detailed in Appendix 2).
Deviations from registered protocol
Deviations from the registered protocol are detailed in Appendix 1. 
The most significant deviation was that only the visual analogue 
scale was used to determine eligibility and assess pain because it 
has established reliability when used with a tablet device38 and we 
believed it to be more acceptable to the age of the participants.
Sample size
We used a minimal clinically important difference on the visual 
analogue scale of 13 mm between groups based on a derivation 
cohort45 and a validation cohort,39 and an adult emergency depart-
ment study of hyoscine butylbromide and acetaminophen for 
abdominal pain.46 With a standard deviation (SD) of 30  mm, 
112 children per group were required to detect a difference at the 
5% 2-sided level of significance with 90% power. The sample size 
was increased to account for dropouts, giving a final sample size of 
115 participants per group.
Statistical analysis
Analyses of efficacy outcomes were based on intention to treat. In 
participants without an 80-minute visual analogue scale score, we 
assumed that the score was unchanged from the preintervention 
pain score. Analysis of adverse effects and of caregiver satisfaction 
was based on a per protocol analysis. We performed inferential sta-
tistics on primary and secondary efficacy outcomes. We used means 
and SDs, frequencies and percentages, and medians and interquar-
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respectively. We compared pain scores at 80  minutes between 
groups using linear regression, adjusting for pain score immediately 
before the intervention. We reported time to achieve at least a 20% 
reduction in preintervention pain using a Kaplan–Meier survival 
analysis. We compared categoric variables using the Pearson χ2 test 
and adverse events using the Fisher exact test. Post hoc regression 
analyses explored the effect of analgesia provided more than 
6 hours before the intervention on the primary outcome with a test 
of interaction. We analyzed the data using SPSS version 24 (IBM 
Corp.). We considered p values less than 0.05 statistically significant.
Ethics approval
The protocol received approval from Western University’s Health 
Sciences Research Ethics Board. The committee would not 
approve the use of a placebo. The trial was monitored by an inde-
pendent data safety monitoring board.











Completed all study 
outcomes
n = 84
Completed all study 
outcomes
n = 84
Excluded  n = 4370  
• Did not meet inclusion criteria  n = 2763  
• Met exclusion criteria  n = 1607  
o History of abdominal disorder*  n = 290  
o Received acetaminophen or HBB within 6 h  n = 260  
o Suspected urinary tract infection (n = 201), 
constipation (n = 151), gynecologic disorder (n = 70), 
gastroesophageal reflux (n = 48), biliary disorder 
(n = 20), testicular disorder (n = 25), foreign body 
ingestion (n = 10), hemodynamic compromise (n = 7), 
renal colic (n = 8), mesenteric adenitis (n = 7), 
pancreatitis (n = 6), vaso-occlusive crisis (n = 1), 
abdominal neoplasm (n = 1), Henoch–Schönlein 
purpura (n = 1)
o Underlying medical condition†  n = 150 
o Hospital admission  n = 99  
o Unable to communicate in English  n = 85   
o Gross lower gastrointestinal bleeding  n = 42  
o Unable to swallow pills  n = 38  
o Pregnant  n = 28  
o Previous enrolment in trial  n = 25  
o Current use of anticholinergic   n = 16  
o Persistent vomiting despite antiemetic   n = 10  
o Acetaminophen or HBB hypersensitivity   n = 6  
o Signs of peritoneal inflammation   n = 2  
Declined consent  n  = 212  
Lost to follow-up  n = 32   
• Did not complete 80-min
pain score  n = 1  
• Did not complete 72-h
survey  n  = 31   
Lost to follow-up  n = 36  
• Did not complete 80-min
pain score  n  = 4  
• Did not complete 72-h
survey  n  = 32   
Figure 1: Flow diagram showing participant selection. *History of abdominal disorder included abdominal surgery (n = 167), abdominal trauma within 
48 hours (n = 42), cyclic vomiting (n = 24), celiac disease (n = 18), hepatobiliary disease (n = 14), bowel obstruction (n = 13) and chromosomal abnormality 
affecting abdominal viscera (n = 12). †Underlying medical conditions included congenital renal anomaly (n = 55), congenital genitourinary anomaly (n = 53), 
inflammatory bowel disease (n = 37), pelvic inflammatory disease (n = 3), neutropenia (n = 1) and tuberculosis (n = 1). Note: HBB = hyoscine butylbromide.
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Results
Of 4818 children screened, 236 were randomly allocated to receive 
hyoscine butylbromide (n  = 120) or acetaminophen (n  = 116) 
(Figure 1). The follow-up survey was completed by 73% of participants 
in both groups. Overall, the mean age was 12.4 (SD 3) years, and 
153 participants (64.8%) were girls. One-third of participants in both 
groups had received analgesia before enrolment (Table 1). Among the 
212 children who were eligible but declined consent, the mean age 
was 11.9 (SD 2.9) years, and 129 (60.8%) were girls.
Primary outcome
Four participants in the hyoscine butylbromide group and 1 par tici-
pant in the acetaminophen group did not complete the 80- minute 
pain assessment. The mean pain scores before the intervention 
were 60 mm (SD 18 mm) and 62 mm (SD 17 mm) in the hyoscine 
butylbromide and acetaminophen groups,  respectively. The 
Table 1 (part 1 of 2): Baseline characteristics of children 
with nonspecific colicky abdominal pain randomized to 
receive hyosine butylbromide or acetaminophen
Characteristic






Female sex 79 (65.8) 74 (63.8)
Age, mean ± SD, yr 12.5 ± 3.1 12.4 ± 2.9
Duration of pain before 
enrolment, median (IQR), h
2 (0.5 to 5) 1.8 (0.5 to 4.8)
Received analgesia before 
enrolment†
    Acetaminophen 13 (10.8) 9 (7.8)
    Ibuprofen 20 (16.7) 24 (20.7)
    Ketorolac 2 (1.7) 4 (3.4)
Received antiemetic in 
emergency department before 
enrolment‡
28 (23.3) 23 (19.8)
Received antacid in emergency 
department before enrolment§
2 (1.7) 2 (1.7)
Comorbidities¶
None 70 (58.3) 72 (62.1)
Gastrointestinal 13 (10.8) 12 (10.3)
    Gastritis 1 (0.8) 2 (1.7)
    Functional abdominal pain 8 (6.7) 6 (5.2)
    Irritable bowel syndrome 1 (0.8) 1 (0.9)
Recurrent abdominal pain of 
childhood
0 (0.0) 2 (1.7)
    Gastroesophageal reflux 2 (1.7) 1 (0.9)
    Functional dyspepsia 1 (0.8) 0 (0.0)
Psychiatric 24 (20.0) 15 (12.9)
    Anxiety 10 (8.3) 10 (8.6)
    Depression 3 (2.5) 3 (2.6)
    Posttraumatic stress disorder 5 (4.2) 0 (0.0)
    Learning disability 1 (0.8) 0 (0.0)
    Eating disorder 0 (0.0) 1 (0.9)
Attention deficit hyperactivity 
disorder
5 (4.2) 1 (0.9)
Otolaryngologic 9 (7.5) 9 (7.8)
    Recurrent otitis media 2 (1.7) 4 (3.4)
    Obstructive sleep apnea 1 (0.8) 0 (0.0)
    Environmental allergies 2 (1.7) 3 (2.6)
    Recurrent tonsillitis 2 (1.7) 2 (1.7)
    Hearing impairment 1 (0.8) 0 (0.0)
    Branchial cleft cyst 1 (0.8) 0 (0.0)
Urologic 2 (1.7) 3 (2.6)
Recurrent urinary tract 
infections
2 (1.7) 2 (1.7)
    IgA nephropathy 0 (0.0) 1 (0.9)
Table 1 (part 2 of 2): Baseline characteristics of children 
with nonspecific colicky abdominal pain randomized to 
receive hyosine butylbromide or acetaminophen
Characteristic






Orthopedic 4 (3.3) 1 (0.9)
    In-toeing 2 (1.7) 1 (0.9)
    Scoliosis 1 (0.8) 0 (0.0)
    Osteochondritis dessecans 1 (0.8) 0 (0.0)
Endocrinologic 4 (3.3) 2 (1.7)
    Turner syndrome 1 (0.8) 1 (0.9)
    Short stature 1 (0.8) 1 (0.9)
    Menorrhagia 1 (0.8) 0 (0.0)
    Type I diabetes mellitus 1 (0.8) 0 (0.0)
Ophthalmologic 0 (0.0) 3 (2.6)
    Strabismus 0 (0.0) 2 (1.7)
    Carotid ophthalmic aneurysm 0 (0.0) 1 (0.9)
Neurologic: migraine 2 (1.7) 1 (0.9)
Respiratory: asthma 5 (4.2) 2 (1.7)
Hematologic: thalassemia 0 (0.0) 1 (0.9)
Other 0 (0.0) 3 (2.6)
    Fibromyalgia 0 (0.0) 1 (0.9)
    Chronic fatigue 0 (0.0) 1 (0.9)
    Maple syrup urine disease 0 (0.0) 1 (0.9)
Note: IgA = immunoglobulin A, IQR = interquartile range, SD = standard deviation.
*Except where noted otherwise.
†A single dose of acetaminophen or ibuprofen was administered before the emergency 
department visit and at least 6 hours before the intervention. Ketorolac was 
administered Intravenously in the emergency department 2.8 to 4.3 hours before the 
intervention in all cases.
‡Ondansetron in all cases.
§Pantoprazole or orally administered mixture of bismuth salicylate and viscous lidocaine.
¶Some participants had more than 1 comorbidity; diagnoses were obtained by 
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corresponding scores at 80 minutes were 29 mm (SD 26 mm) and 
30 mm (SD 29 mm), with an adjusted between-group difference of 1 
(95% confidence interval –7 to 7) (Table 2). There was no significant 
effect of any preintervention analgesia (p = 0.9), or acetaminophen 
(p = 0.8), ibuprofen (p = 0.5) or ketorolac (p = 0.99) specifically, upon 
the results of the primary analysis.
Secondary outcomes
Rescue analgesia was administered to 4 participants (3.3%) in the 
hyoscine butylbromide and 1 participant (0.9%) in the acetamino-
phen group (p  = 0.2). In all cases, ibuprofen or ketorolac was 
administered after the 80-minute pain assessment. A pain score 
less than 30 mm 80 minutes after the intervention was reported by 
66 participants (55.0%) in the hyoscine butylbromide group and 
63 participants (54.3%) in the acetaminophen group (p = 0.9).
Adverse effects
Adverse effects in the emergency department were reported by 
32/116 (27.6%) and 28/115 (24.3%) participants in the hyoscine butyl-
bromide and acetaminophen groups, respectively (p = 0.5) (Table 3). 
There were no serious adverse effects or missed surgical diagnoses.
Other outcomes
Caregiver satisfaction was high with both hyoscine butylbromide 
(median Likert score 5 [IQR 4 to 5]) and acetaminophen (median 
score 5 [IQR 3 to 5]). The mean visual analogue scale pain scores 
declined steadily after the intervention in both groups (Table 2). The 
median time to 20% reduction in preintervention pain score was 
22.5 (IQR 15 to 60) minutes in the hyoscine butylbromide and 30.0 
(IQR 15 to 60) minutes in the acetaminophen group (Figure 2). The 
median length of emergency department stay was 230.5 (IQR 189.8 
to 292.3) minutes in the hyoscine butylbromide group and 236.0 
(IQR 191.3 to 291.0) minutes in the acetaminophen group. Most par-
ticipants in both groups were discharged from the emergency 
department, and few returned to a health care provider for abdom-
inal pain (Table 4). Pain after discharge was reported by 46/84 
(54.8%) of participants in the hyoscine butylbromide and 41/84 
(48.8%) of those in the acetaminophen group.
Table 2: Mean pain scores*
Time







Before intervention 60.3 ± 17.9 62.3 ± 16.5 –
After intervention
    15 min 45.9 ± 22.5 45.5 ± 23.8 –
    30 min 42.1 ± 22.9 39.3 ± 24.1 –
    45 min 37.1 ± 24.4 36.7 ± 26.8 –
    60 min 33.4 ± 26.4 33.7 ± 27.9 –
    80 min 29.4 ± 26.4 30.1 ± 28.8 0.7 (–6.9 to 7.3)
Note: CI = confidence interval, SD = standard deviation.
*Assessed with a 100 mm visual analogue scale.
†Represents between-group difference in pain scores 80 minutes after the intervention, adjusted for preintervention pain scores.
Table 3: Adverse effects in the emergency department and 
at 72-hour follow-up
Adverse effect






n = 116* n = 115*
Any adverse effect† 32 (27.6) 28 (24.3) 0.5
Nausea 10 (8.6) 12 (10.4)
Dizziness 15 (12.9) 8 (7.0)
Dry mouth 5 (4.3) 7 (6.1)
Photosensitivity 9 (7.8) 3 (2.6)
Vomiting 3 (2.6) 1 (0.9)
Constipation 1 (0.9) 3 (2.6)
Dry skin 2 (1.7) 2 (1.7)
Racing heart 2 (1.7) 2 (1.7)
Headache 1 (0.9) 2 (1.7)
Diarrhea 0 (0.0) 1 (0.9)
Sweating 0 (0.0) 1 (0.9)
Drowsiness 1 (0.9) 0 (0.0)
72-h follow-up n = 84‡ n = 84‡
Any adverse effect† 12 (14.3) 12 (14.3) 0.99
Dry mouth 3 (3.6) 4 (4.8)
Constipation 0 (0.0) 1 (1.2)
Vomiting 0 (0.0) 2 (2.4)
Dizziness 4 (4.8) 0 (0.0)
Light sensitivity 1 (1.2) 1 (1.2)
Hives 0 (0.0) 1 (1.2)
Drowsiness 4 (4.8) 2 (2.4)
Headache 2 (2.4) 2 (2.4)
*Denominator reflects the number of participants who completed the 80-minute pain score.
†Some participants reported more than 1 adverse effect.
‡Denominator reflects the number of participants for whom telephone follow-up alone 
was performed.
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Interpretation
In this randomized controlled trial, we found that hyoscine butylbro-
mide was not superior to acetaminophen in children with nonspecific 
abdominal pain in the highly selected patients randomized. Our find-
ings suggest that either agent may be routinely considered for chil-
dren with nonspecific colicky abdominal pain in the emergency 
department. Among adults, a reduction of 30 mm or more on a visual 
analogue scale corresponds to “adequate pain control,”47 and a 
decrease of 30% or more from baseline has been deemed clinically 
significant in irritable bowel syndrome.48 We observed a decrease 
from baseline of roughly 50% in both groups, but this was achieved 
by less than 60% of participants. However, caregiver satisfaction was 
high in both groups. Pain severity at discharge and satisfaction with 
pediatric emergency department care are poorly correlated,49,50 and 
caregiver satisfaction may reflect a “personal evaluation of health 
care services and providers,”51 along with the message that pain man-
agement is a priority.49,52 Ongoing pain after discharge was reported 
by about half of participants in both groups, which shows the need 
for appropriate discharge instructions regarding analgesia. More than 
half of participants in both groups received analgesia before enrol-
ment. The possibility of a residual analgesic effect complementing 
that of the intervention was unlikely because we excluded partici-
pants who had received analgesia within 6 hours, the therapeutic 
window of both hyoscine butylbromide and acetaminophen.
Our findings are in keeping with those of adult studies of orally 
administered hyoscine butylbromide for colicky abdominal pain that 
showed decreases in pain of 59%53 and 30%.54 In the only known 
 pediatric study of hyoscine butylbromide, the medication was com-











































No. at risk (acetaminophens)
No. at risk (hyoscine butylbromide)
Figure 2: Kaplan–Meier survival analysis, showing time to reduction in visual analogue scale pain score after intervention.
Table 4: Discharge diagnoses, disposition from emergency 
department and follow-up
Variable







Abdominal pain not yet 
determined
77 (66.4) 77 (67.0)
Gastroenteritis 37 (31.9) 27 (23.5)
Functional abdominal pain 0 (0.0) 10 (8.7)
Irritable bowel syndrome 2 (1.7) 1 (0.9)
Disposition
Admitted† 3 (2.6) 2 (1.7)
Discharged 113 (97.4) 113 (98.3)
72-h follow-up‡
Returned to medical care for 
abdominal pain
6 (5.2) 4 (3.5)
Hospital admission 1 (0.9) 0 (0.0)




*Based largely on physician judgment.
†Admitted by the pediatric general surgery service for observation.
‡Data obtained via telephone survey; for participants who could not be reached by 
telephone, data were obtained from the electronic medical record and therefore reflect 
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preparation, in children with recurrent gastrointestinal or urethral 
spasms; the study reported that both agents were beneficial, with few 
adverse effects.30 Although hyoscine butylbromide is an antimusca-
rinic agent, the butylbromide moiety limits systemic absorption, and, 
therefore, systemic anticholinergic effects are uncommon.28,29,46 To 
our knowledge, no pediatric studies have explored acetaminophen 
for nonspecific abdominal pain. Remington-Hobbs and colleagues46 
found that, in adults, acetaminophen was superior to intravenously 
given hyoscine butylbromide for “undifferentiated” abdominal pain. 
Hyoscine butylbromide is available in Canadian emergency depart-
ments but must be ingested as an intact pill. Acetaminophen may be 
a more feasible option because it is available over the counter and 
inexpensive, and can be administered to children of all ages. Adopting 
a therapy with a time to effective analgesia of 60–80 minutes post-
intervention may be difficult in an acute care setting. In our study, the 
median length of stay was more than 3.5 hours in both groups, consis-
tent with data from a US cohort of children with “undifferentiated” 
abdominal pain (3.4 h).5 We did not record the number of diagnostic 
tests, but tests may have contributed to length of stay,55,56 and triage-
based directives may facilitate more timely analgesia and discharge.57
Future studies should explore the effectiveness of a higher dos-
age of hyoscine butylbromide (20 mg), hyoscine patches or combin-
ing pharmacologic therapies with nonpharmacologic strategies 
such as cognitive behaviour therapy.58 Where possible, should eth-
ical approval allow, studies could include a placebo arm to test 
whether an active comparator is associated with earlier symptom 
resolution and whether the benefits of therapy offset the costs.
Limitations
The observed decreases in pain in our study may have been due to 
the study medications, the natural history of nonspecific abdom-
inal pain,59 satisfaction that diagnostic investigations were negative 
or “tincture of time.” Definitively attributing analgesia to the inter-
vention would have been possible with a placebo arm. Neverthe-
less, it remains likely that participants in both groups benefited 
from the interventions. Following pain duration of roughly 2 hours 
before enrolment, pain scores had decreased by about 50% in both 
groups 60–80 minutes after the intervention, the time of peak anal-
gesic effectiveness of both agents.19,34,35 In adult emergency depart-
ment patients, intravenously administered hyoscine butylbromide 
and orally administered acetaminophen were associated with 
decreases greater than 50% in “undifferentiated” abdominal pain 
at 60 minutes.46 In the present study, many screened patients were 
excluded because of suspected underlying causes of the abdominal 
pain, which may limit external generalizability. We focused on non-
specific pain because it is the most common form of abdominal 
pain among children presenting to the emergency department.8,9 
We limited enrolment to children with colicky pain because we 
believed it was amenable to relief with hyoscine butylbromide, an 
inhibitor of acetylcholine-mediated intestinal smooth muscle con-
traction.19 Furthermore, we limited enrolment to patients able to 
verbalize symptoms consistent with colicky abdominal pain; thus, 
our findings may not apply to patients with other types of abdom-
inal pain. Although we were able to determine return visits for 
almost all participants, for roughly a quarter, we could not deter-
mine whether they had persistent pain or delayed adverse effects.
Conclusion
Hyoscine butylbromide was not superior to acetaminophen in 
children with nonspecific colicky abdominal pain, but both were 
associated with a clinically important benefit. Our results suggest 
that either hyoscine butylbromide or acetaminophen can be con-
sidered for children with nonspecific colicky abdominal pain, the 
latter being more practical. Definitive recommendations require a 
placebo-controlled trial to determine whether the benefits of pro-
viding analgesia are clinically important compared to no analgesia 
with respect to outcomes such as emergency department length 
of stay, satisfaction and side effects.
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